The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•28 April 2026•

1 min read

Annovis Bio Announces Positive Phase 2/3 Results for Alzheimer's Drug Buntanetap

Key Facts

1Buntanetap improved cognition in early Alzheimer's patients and reduced neurotoxic proteins and biomarkers of neuroinflammation.

2The study results were published in the peer-reviewed journal Nature NPJ Dementia, supporting the ongoing pivotal Phase 3 study.

Annovis Bio, Inc. has announced the publication of its Phase 2/3 clinical trial results for buntanetap in the peer-reviewed journal Nature NPJ Dementia. The study demonstrated that the drug significantly improved cognition in patients with mild to moderate Alzheimer's disease. Furthermore, buntanetap was shown to reduce neurotoxic proteins and biomarkers associated with neuroinflammation, validating its unique mechanism of action. These published findings provide a robust scientific foundation for the company's ongoing pivotal Phase 3 study, which has already reached 80% enrollment. This milestone marks a critical step forward in the drug's regulatory pathway and clinical validation. The positive data publication is expected to bolster investor confidence in the company's long-term biotechnology pipeline.